Syntetisk biologi: er ArcticZymes den nye ESG yndlingen?
Jeg har lusket litt rundt på internettet igjen og kom over dette. Helt nytt for meg og enda et ben å stå på når aksjen plutselig må regnes inn i ESG sektoren og det grønne skiftet:
« Redox enzymes require co-factors and redox partners, and there is a considerable degree of cooperativity between different enzyme classes.[1] Understanding and eventually engineering the efficient degradation of lignocellulose by these enzyme systems, a key ability in a future circular bioeconomy, requires a transdisciplinary approach far beyond “simple” enzyme discovery.
OXYMOD combines life sciences (enzyme biochemistry, enzyme production techno- logy, microbial biotechnology, high through- put screening, advanced analytics), ICT (bioinformatics, big data handling), mathe- matical sciences (enzyme systems modelling, process modelling) and engineer- ing (enzyme evolution, synthetic biology) for developing new and optimized biocatalytic systems for industrial application, primarily within the agricultural and forest sectors. It is therefore highly relevant as a project in the Norwegian Centre for Digital Life (DLN). Besides the enzymes and enzyme systems themselves, additional innovations from OXYMOD concern the generation of well- defined products streams, primarily sugars from (hemi-)cellulose and aromatic building
blocks from lignin for a variety of downstream applications (e.g. biofuels & bioplastics).»
Partnere: Borregaard og Norske Skog (!) i regi av NTNU.
Man kan lese mer her: https://www.ntnu.no/blogger/reset/wp-content/uploads/sites/32/2017/10/DLN-OXYMOD.pdf
Dokumentet er noen år gammelt og jeg lurer fælt på hvordan dette går. OXYMOD har publisert en rekke artikler i 2020 uten at jeg ble klokere av å lese dem.
Jethro har flere ganger referert til at de jobber med «noe» innen syntetisk biologi. Dette er det mest konkrete jeg har greid å finne. Antakelig enda på forsøksstadiet, så litt tålamod må man vel smøre seg med. Men jeg syntes dette var så interessant at jeg dumper det her.
Redigert 20.01.2021 kl 02:18
Du må logge inn for å svare
Midd30
01.01.2021 kl 17:14
799
Ser Vectron Biosolutions er nevnt i dokumentet til NTNU ovenfor.
Ref melding fra des 2018. Interessant!
ArcticZymes and Vectron Biosolutions sign license agreement on recombinant enzyme expression technology
(Tromsø 20. December 2018) Biotec Pharmacon’s (OSE: Biotec) subsidiary ArcticZymes and Vectron Biosolutions AS (Vectron) have signed a non-exclusive license agreement for recombinant manufacturing of enzymes.
Ref melding fra des 2018. Interessant!
ArcticZymes and Vectron Biosolutions sign license agreement on recombinant enzyme expression technology
(Tromsø 20. December 2018) Biotec Pharmacon’s (OSE: Biotec) subsidiary ArcticZymes and Vectron Biosolutions AS (Vectron) have signed a non-exclusive license agreement for recombinant manufacturing of enzymes.